Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agencyls Committee for Medicinal Products for Human Use

DOI: 10.1208/s12249-017-0892-0
AAPS PharmSciTech, 2018, 19, 489-511.

#	Paper	IF	Citations
6	Investigation of quality review issues and the association with application characteristics for new drug applications in first-cycle reviews. *Regulatory Toxicology and Pharmacology*, **2019**, 108, 104448	3.4	
5	Biosimilars: development and investigation using achievements in modern biotechnology. *Diabetes Mellitus*, **2021**, 23, 548-560	1.6	1
4	Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities. *Pharmaceuticals*, **2021**, 14,	5.2	0
3	Biosimilars: evolution of approaches to the development, regulation, life cycle control and interchangeability management. *Remedium Journal About the Russian Market of Medicines and Medical Equipment*, **2021**, 56-68	0.9	
2	Common deficiencies found in generic Finished Pharmaceutical Product (FPP) applications submitted for registration to the South African Health Products Regulatory Authority (SAHPRA).. *Journal of Pharmaceutical Policy and Practice*, **2022**, 15, 6	3.2	0
1	Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia. *Drug Discovery Today*, **2022**,	8.8	